tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Syntara Limited Showcases Promising Amsulostat Data at ASH Meeting
Company AnnouncementsSyntara Limited Showcases Promising Amsulostat Data at ASH Meeting
11d ago
Syntara Limited Highlights Uncertainty in Future Projections
PremiumCompany Announcements
Syntara Limited Highlights Uncertainty in Future Projections
20d ago
Syntara Limited Announces Director’s Interest Change
PremiumCompany Announcements
Syntara Limited Announces Director’s Interest Change
20d ago
Syntara Limited Announces Director’s Increased Share Options
PremiumCompany Announcements
Syntara Limited Announces Director’s Increased Share Options
20d ago
Syntara Limited Issues New Performance Rights
PremiumCompany Announcements
Syntara Limited Issues New Performance Rights
20d ago
Syntara Limited Issues Performance Rights Under Employee Incentive Scheme
PremiumCompany AnnouncementsSyntara Limited Issues Performance Rights Under Employee Incentive Scheme
20d ago
Syntara Advances SNT-9465 in Clinical Trials for Skin Scarring Treatment
Premium
Company Announcements
Syntara Advances SNT-9465 in Clinical Trials for Skin Scarring Treatment
20d ago
Syntara Limited Hosts Webinar on Skin Scarring Treatment and Drug Development
Premium
Company Announcements
Syntara Limited Hosts Webinar on Skin Scarring Treatment and Drug Development
22d ago
Syntara Limited Launches Phase 2 Trial for MDS Treatment in Australia
PremiumCompany Announcements
Syntara Limited Launches Phase 2 Trial for MDS Treatment in Australia
25d ago
Syntara Limited AGM: Key Resolutions Passed, One Withdrawn
PremiumCompany Announcements
Syntara Limited AGM: Key Resolutions Passed, One Withdrawn
26d ago
Syntara Limited Highlights Leadership Expertise at Annual General Meeting
PremiumCompany Announcements
Syntara Limited Highlights Leadership Expertise at Annual General Meeting
26d ago
Syntara Limited Advances Clinical Programs with Promising Results and Strong Financial Position
PremiumCompany Announcements
Syntara Limited Advances Clinical Programs with Promising Results and Strong Financial Position
26d ago
Syntara Limited Gains EU Orphan Drug Designation for Amsulostat
PremiumCompany AnnouncementsSyntara Limited Gains EU Orphan Drug Designation for Amsulostat
29d ago
Syntara Limited Reports Promising Phase 2a Results for Amsulostat in Myelofibrosis
Premium
Company Announcements
Syntara Limited Reports Promising Phase 2a Results for Amsulostat in Myelofibrosis
2M ago
Syntara Limited Announces 2025 Virtual AGM
Premium
Company Announcements
Syntara Limited Announces 2025 Virtual AGM
2M ago
Syntara Limited Announces Virtual AGM for 2025
PremiumCompany Announcements
Syntara Limited Announces Virtual AGM for 2025
3M ago
Pharmaxis Ltd Announces Positive Phase 2a Results for Amsulostat in Myelofibrosis
PremiumCompany Announcements
Pharmaxis Ltd Announces Positive Phase 2a Results for Amsulostat in Myelofibrosis
3M ago
Syntara Limited Reports Promising Phase 2a Results for Amsulostat in Myelofibrosis Treatment
PremiumCompany Announcements
Syntara Limited Reports Promising Phase 2a Results for Amsulostat in Myelofibrosis Treatment
3M ago
Syntara Strengthens Leadership for Amsulostat Development
PremiumCompany Announcements
Syntara Strengthens Leadership for Amsulostat Development
3M ago
Syntara Limited Secures A$5.6 Million R&D Tax Incentive
PremiumCompany AnnouncementsSyntara Limited Secures A$5.6 Million R&D Tax Incentive
3M ago
Pharmaxis Ltd Highlights Strategic Initiatives at Healthcare Conference
Premium
Company Announcements
Pharmaxis Ltd Highlights Strategic Initiatives at Healthcare Conference
3M ago
Pharmaxis Receives FDA Guidance on Amsulostat’s Clinical Pathway
Premium
Company Announcements
Pharmaxis Receives FDA Guidance on Amsulostat’s Clinical Pathway
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >